Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-21 4:15 pm Sale | 2025-08-21 | 13D | Keros Therapeutics, Inc. KROS | ADAR1 Capital Management, LLC | 5,389,264 13.270% | -1,700 (-0.03%) | Filing History |
| 2025-05-14 5:49 pm Purchase | 2025-05-07 | 13G | Keros Therapeutics, Inc. KROS | Madison Avenue Partners LP | 2,614,402 6.400% | 2,614,402 (New Position) | Filing History |
| 2025-05-12 11:29 am Unchanged | 2025-05-12 | 13D | Keros Therapeutics, Inc. KROS | ADAR1 Capital Management, LLC | 5,390,964 13.270% | 0 (Unchanged) | Filing History |
| 2025-05-08 4:39 pm Unchanged | 2025-05-08 | 13D | Keros Therapeutics, Inc. KROS | ADAR1 Capital Management, LLC | 5,390,964 13.270% | 0 (Unchanged) | Filing History |
| 2025-05-05 2:03 pm Sale | 2025-04-30 | 13G | Keros Therapeutics, Inc. KROS | JPMORGAN CHASE & CO JPM | 0 0.000% | -2,587,146 (Position Closed) | Filing |
| 2025-05-02 09:59 am Purchase | 2025-03-31 | 13G | Keros Therapeutics, Inc. KROS | JPMORGAN CHASE & CO JPM | 2,587,146 6.300% | 2,587,146 (New Position) | Filing History |
| 2025-04-30 11:23 am Purchase | 2025-03-31 | 13G | Keros Therapeutics, Inc. KROS | VANGUARD GROUP INC | 2,566,321 6.320% | 2,566,321 (New Position) | Filing History |
| 2025-04-28 6:43 pm Unchanged | 2025-04-24 | 13D | Keros Therapeutics, Inc. KROS | ADAR1 Capital Management, LLC | 5,390,964 13.290% | 0 (Unchanged) | Filing History |
| 2025-04-18 5:10 pm Purchase | 2025-04-17 | 13D | Keros Therapeutics, Inc. KROS | Pontifax Management 4 GP (2015) Ltd. | 4,787,331 11.800% | 52,824 (+1.12%) | Filing History |
| 2025-04-11 8:32 pm Purchase | 2025-04-04 | 13D | Keros Therapeutics, Inc. KROS | ADAR1 Capital Management, LLC | 5,390,964 13.290% | 5,390,964 (New Position) | Filing History |
| 2025-02-14 4:12 pm Sale | 2024-12-31 | 13G | Keros Therapeutics, Inc. KROS | ALKEON CAPITAL MANAGEMENT LLC | 1,101,000 2.700% | -397,907 (-26.55%) | Filing History |
| 2025-02-07 10:23 am Sale | 2025-01-31 | 13G | Keros Therapeutics, Inc. KROS | FMR LLC | 704,472 1.700% | -3,169,732 (-81.82%) | Filing History |
| 2024-02-13 6:38 pm Purchase | 2023-12-31 | 13G | Keros Therapeutics, Inc. KROS | ALKEON CAPITAL MANAGEMENT LLC | 1,498,907 5.000% | 106,505 (+7.65%) | Filing History |
| 2024-02-09 09:16 am Purchase | 2024-02-08 | 13G | Keros Therapeutics, Inc. KROS | FMR LLC | 3,874,204 12.931% | 195,115 (+5.30%) | Filing History |
| 2024-01-26 5:26 pm Purchase | 2023-12-31 | 13G | Keros Therapeutics, Inc. KROS | BlackRock Inc. BLK | 2,036,788 6.800% | 398,462 (+24.32%) | Filing History |
| 2023-12-13 5:20 pm Unchanged | 2023-12-11 | 13D | Keros Therapeutics, Inc. KROS | ORBIMED ADVISORS LLC | 1,268,734 4.200% | 0 (Unchanged) | Filing History |
| 2023-02-14 09:53 am Sale | 2022-12-31 | 13G | Keros Therapeutics, Inc. KROS | Deep Track Capital LP | 0 0.000% | -1,300,000 (Position Closed) | Filing History |
| 2023-02-13 10:13 am Purchase | 2022-12-31 | 13G | Keros Therapeutics, Inc. KROS | ALKEON CAPITAL MANAGEMENT LLC | 1,392,402 5.100% | 1,392,402 (New Position) | Filing History |
| 2023-02-09 12:48 pm Purchase | 2023-02-09 | 13G | Keros Therapeutics, Inc. KROS | FMR LLC | 3,679,089 13.357% | 174,291 (+4.97%) | Filing History |
| 2023-02-07 11:06 am Purchase | 2022-12-31 | 13G | Keros Therapeutics, Inc. KROS | BlackRock Inc. BLK | 1,638,326 5.900% | 351,800 (+27.34%) | Filing History |